News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vitality Biopharma Announces International Patent Filing For Cannabinoid Pharmaceuticals



11/11/2016 2:45:43 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

LOS ANGELES, CA--(Marketwired - November 09, 2016) - Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international PCT patent application, a milestone in its development of a platform of cannabinoid pharmaceuticals.

The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. Vitality Biopharma's patent filing includes details that were previously submitted in three separate U.S. provisional applications, and includes 79 patent claims and almost 200 individual compounds, including novel glycoside prodrugs of the most abundant phytocannabinoids, THC and cannabidiol (CBD), as well as a variety of other phytocannabinoids and endocannabinoids. The patent application includes additional compounds, such as vanilloids, a class of molecules that could provide sustained pain relief through targeting of the TRPV1 receptor, and enzymatic biosynthesis methods that the Company uses internally for drug manufacturing.

There are 151 member countries within the PCT worldwide, so near global patent coverage can be obtained through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, and many other countries. The original priority date for this filing was September 22, 2015, therefore coverage of any underlying patent claims would extend for 20 years until 2035 in the United States, and may be subject to patent term extensions that would enable years of additional protection.

"This is a significant milestone enabled by our team's discovery and production of a versatile new portfolio of cannabinoid pharmaceuticals," said Robert Brooke, Chief Executive Officer of Vitality Biopharma. "The clinical data emerging on the use of cannabinoids for inflammatory bowel disease, opiate addiction, and many other serious disorders is inspiring, and our team is now working internally and through collaborators to develop key therapeutic applications for our compounds."

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


Contact
Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES